MRNA and Gene Editing: Late Breaking Therapies in Liver Diseases

Overview

Journal Hepatology

Specialty Gastroenterology

Date 2022 Mar 4

PMID 35243655

Authors

Nerea Zabaleta

Laura Torella

Nicholas D Weber

Gloria Gonzalez-Aseguinolaza

Affiliations

Soon will be listed here.

Abstract

The efficient delivery of RNA molecules to restore the expression of a missing or inadequately functioning protein in a target cell and the intentional specific modification of the host genome using engineered nucleases represent therapeutic concepts that are revolutionizing modern medicine. The initiation of several clinical trials using these approaches to treat metabolic liver disorders as well as the recently reported remarkable results obtained by patients with transthyretin amyloidosis highlight the advances in this field and show the potential of these therapies to treat these diseases safely and efficaciously. These advances have been possible due, firstly, to significant improvements made in RNA chemistry that increase its stability and prevent activation of the innate immune response and, secondly, to the development of very efficient liver-targeted RNA delivery systems. In parallel, the breakout of CRISPR/CRISPR-associated 9-based technology in the gene editing field has marked a turning point in in vivo modification of the cellular genome with therapeutic purposes, which can be based on gene supplementation, correction, or silencing. In the coming years we are likely to witness the therapeutic potential of these two strategies both separately and in combination. In this review we summarize the preclinical data obtained in animal models treated with mRNA as a therapeutic agent and discuss the different gene editing strategies applied to the treatment of liver diseases, highlighting both their therapeutic efficacy as well as safety concerns.

Citing Articles

High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics.

Xiao Y, Lian X, Sun Y, Sung Y, Vaidya A, Chen Z Nat Mater. 2025; .

PMID: 40021827 DOI: 10.1038/s41563-024-02116-3.

Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics.

Ma X, Huang T, Chen X, Li Q, Liao M, Fu L Signal Transduct Target Ther. 2025; 10(1):63.

PMID: 39920130 PMC: 11806117. DOI: 10.1038/s41392-024-02104-8.

IL-22: A key inflammatory mediator as a biomarker and potential therapeutic target for lung cancer.

Xu L, Cao P, Wang J, Zhang P, Hu S, Cheng C Heliyon. 2024; 10(17):e35901.

PMID: 39263114 PMC: 11387261. DOI: 10.1016/j.heliyon.2024.e35901.

Gene therapy for polygenic or complex diseases.

Wu T, Hu Y, Tang L Biomark Res. 2024; 12(1):99.

PMID: 39232780 PMC: 11375922. DOI: 10.1186/s40364-024-00618-5.

Optimizing 5'UTRs for mRNA-delivered gene editing using deep learning.

Castillo-Hair S, Fedak S, Wang B, Linder J, Havens K, Certo M Nat Commun. 2024; 15(1):5284.

PMID: 38902240 PMC: 11189900. DOI: 10.1038/s41467-024-49508-2.

References

Chen P, Hussmann J, Yan J, Knipping F, Ravisankar P, Chen P . Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell. 2021; 184(22):5635-5652.e29. PMC: 8584034. DOI: 10.1016/j.cell.2021.09.018. View

Yang T, Poenisch M, Khanal R, Hu Q, Dai Z, Li R . Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. J Hepatol. 2021; 75(6):1420-1433. DOI: 10.1016/j.jhep.2021.08.011. View

Turchiano G, Andrieux G, Klermund J, Blattner G, Pennucci V, El Gaz M . Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq. Cell Stem Cell. 2021; 28(6):1136-1147.e5. DOI: 10.1016/j.stem.2021.02.002. View

Mevel M, Kamaly N, Carmona S, Oliver M, Jorgensen M, Crowther C . DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J Control Release. 2009; 143(2):222-32. DOI: 10.1016/j.jconrel.2009.12.001. View

Berraondo P, Martini P, Avila M, Fontanellas A . Messenger RNA therapy for rare genetic metabolic diseases. Gut. 2019; 68(7):1323-1330. DOI: 10.1136/gutjnl-2019-318269. View

Gillmore J, Gane E, Taubel J, Kao J, Fontana M, Maitland M . CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021; 385(6):493-502. DOI: 10.1056/NEJMoa2107454. View

Gill R, Sterling R . Acute liver failure. J Clin Gastroenterol. 2001; 33(3):191-8. DOI: 10.1097/00004836-200109000-00005. View

Li N, Gou S, Wang J, Zhang Q, Huang X, Xie J . CRISPR/Cas9-Mediated Gene Correction in Newborn Rabbits with Hereditary Tyrosinemia Type I. Mol Ther. 2020; 29(3):1001-1015. PMC: 7934638. DOI: 10.1016/j.ymthe.2020.11.023. View

Zhu X, Yin L, Theisen M, Zhuo J, Siddiqui S, Levy B . Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates. Am J Hum Genet. 2019; 104(4):625-637. PMC: 6451694. DOI: 10.1016/j.ajhg.2019.02.003. View

10.

Ou L, Przybilla M, Ahlat O, Kim S, Overn P, Jarnes J . A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I. Mol Ther. 2020; 28(6):1442-1454. PMC: 7264433. DOI: 10.1016/j.ymthe.2020.03.018. View

11.

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

12.

Ramaswamy S, Tonnu N, Tachikawa K, Limphong P, Vega J, Karmali P . Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc Natl Acad Sci U S A. 2017; 114(10):E1941-E1950. PMC: 5347596. DOI: 10.1073/pnas.1619653114. View

13.

Pankowicz F, Barzi M, Legras X, Hubert L, Mi T, Tomolonis J . Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia. Nat Commun. 2016; 7:12642. PMC: 5013601. DOI: 10.1038/ncomms12642. View

14.

Schene I, Joore I, Oka R, Mokry M, van Vugt A, van Boxtel R . Prime editing for functional repair in patient-derived disease models. Nat Commun. 2020; 11(1):5352. PMC: 7584657. DOI: 10.1038/s41467-020-19136-7. View

15.

DeRosa F, Guild B, Karve S, Smith L, Love K, Dorkin J . Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. Gene Ther. 2016; 23(10):699-707. PMC: 5059749. DOI: 10.1038/gt.2016.46. View

16.

Nelson C, Wu Y, Gemberling M, Oliver M, Waller M, Bohning J . Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med. 2019; 25(3):427-432. PMC: 6455975. DOI: 10.1038/s41591-019-0344-3. View

17.

Li B, Luo X, Deng B, Wang J, McComb D, Shi Y . An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo. Nano Lett. 2015; 15(12):8099-107. PMC: 4869688. DOI: 10.1021/acs.nanolett.5b03528. View

18.

Zhang X, Zhao W, Nguyen G, Zhang C, Zeng C, Yan J . Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing. Sci Adv. 2020; 6(34). PMC: 7442477. DOI: 10.1126/sciadv.abc2315. View

19.

Cheng Q, Wei T, Jia Y, Farbiak L, Zhou K, Zhang S . Dendrimer-Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I. Adv Mater. 2018; 30(52):e1805308. DOI: 10.1002/adma.201805308. View

20.

Villiger L, Rothgangl T, Witzigmann D, Oka R, Lin P, Qi W . In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA. Nat Biomed Eng. 2021; 5(2):179-189. PMC: 7610981. DOI: 10.1038/s41551-020-00671-z. View